ABL1 and hematopoietic and lymphoid system neoplasm: CML is a hematologic neoplasm sustained by the constitutive activation of the BCR::ABL1 fusion kinase that can successfully be targeted with TKIs, so that most CML patients nowadays obtain durable remissions.